CEO, CTO, Director
Ziteo Medical
Ziteo is developing high-definition SPECT imaging technology to enhance the detection and localization of curable tumors, enabling earlier diagnosis and personalized treatment options. This approach aims to improve patient outcomes by facilitating timely interventions before cancer metastasis occurs.
- Biotechnology
- Healthcare Technology
- Medical Devices
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Current SPECT imaging technology often lacks the resolution needed for early and precise detection of curable tumors, hindering timely diagnosis and personalized treatment planning. This limitation can lead to delayed interventions and potentially poorer patient outcomes.
Solution
Ziteo is developing high-definition SPECT (single-photon emission computed tomography) imaging technology designed to improve the detection and localization of tumors at earlier stages. Their system aims to provide superior image resolution and quality compared to existing clinical systems, enabling physicians to diagnose cancer sooner and with greater accuracy. By facilitating earlier detection, Ziteo's technology supports more effective, personalized treatment options, potentially improving patient survival rates and quality of life. The company's goal is to advance medical imaging to enable timely interventions before cancer metastasis occurs.
Target Audience
The primary target audience includes physicians and medical professionals specializing in oncology and nuclear medicine, as well as hospitals and cancer centers seeking advanced imaging solutions.
Features
- High-definition SPECT imaging for enhanced tumor detection and localization.
- Superior image resolution and quality compared to state-of-the-art clinical systems.
- Technology designed to enable earlier cancer diagnosis before metastasis.